MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hdi.13198

Медицинская библиотека · Hemodialysis international. International Symposium on Home Hemodialysis · 2025

Hepatitis C Treatment With Generic Sofosbuvir-Based Regimens in Patients Undergoing Hemodialysis.

Afredj Nawal, Boumendjel Mustapha, Mahiou Hassen, Drir Othmane, Cheikh Ibtissem Ouled, Belimi Hibatallah, Kerbouche Rafik, Guessab Nawal, Zaidi Arezki, Boutra Fouad, Nakmouche M'hamed, Debzi Nabil

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

To assess the efficacy and safety of locally manufactured generic sofosbuvir-based direct-acting antivirals in the treatment of Hepatitis C virus (HCV) infected patients on maintenance hemodialysis.

PATIENTS AND

METHODS

We have conducted a retrospective multicenter study including patients on maintenance hemodialysis, treated with sofosbuvir-based regimens between 01/01/2017 and 09/30/2021. Patients were treated for 12 or 24 weeks, with sofosbuvir 400 mg + ledipasvir 90 mg 3 times/week, or sofosbuvir 3 times/week + daclatasvir 60 mg/d, or sofosbuvir + daclatasvir in coformulation, 3 times/week. Sustained virological response was defined as a negative HCV RNA test 12 weeks after treatment. The occurrence of serious adverse events during treatment defines intolerance to treatment. Statistical analysis was performed using SPSS software (version 25).

RESULTS

A total of 120 patients were treated; the mean age was 50 ± 14.17 years [18-78], 50% were men. Twenty-two patients (n = 22; 18.3%) were previously treated with pegylated Interferon. Genotype 1 was predominant (n = 68; 82%). Most of the patients (n = 53; 44.2%) had no significant fibrosis, and 24 (20%) had cirrhosis. The SVR rate was 93.3% (CI 95% [88.8; 97.8]) (n = 112), the serious adverse events rate was 10.8% (CI 95% [0.054-0.166]) (n = 13), including 2 deaths unrelated to direct-acting antivirals. Early treatment discontinuation occurred in 5.8% (n = 7), and a relapse in 0.8% (n = 1). On multivariate analysis, risk factors for serious adverse events included advanced liver fibrosis, thrombocytopenia, hypoalbuminemia, high bilirubin level, and pre-treatment status.

CONCLUSION

Locally manufactured generic sofosbuvir-based regimens are safe and effective in maintenance hemodialysis patients. However, they should be closely monitored to manage comorbidities and complications during treatment.

Для цитирования: Afredj Nawal, Boumendjel Mustapha, Mahiou Hassen, Drir Othmane, Cheikh Ibtissem Ouled, Belimi Hibatallah, Kerbouche Rafik, Guessab Nawal, Zaidi Arezki, Boutra Fouad, Nakmouche M'hamed, Debzi Nabil. Hepatitis C Treatment With Generic Sofosbuvir-Based Regimens in Patients Undergoing Hemodialysis.. Hemodialysis international. International Symposium on Home Hemodialysis. 2025. DOI: 10.1111/hdi.13198.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.